Venovenous extracorporeal membrane oxygenation for COVID-19 associated severe respiratory failure Case series from a Hungarian tertiary centre /
Introduction Venovenous extracorporeal membrane oxygenation (V-V ECMO) is recommended for the support of patients with severe COVID-19 associated severe respiratory failure (SRF). We report the characteristics and outcome of COVID-19 patients supported with V-V ECMO in a Hungarian centre. Methods We...
Elmentve itt :
| Szerzők: | |
|---|---|
| Dokumentumtípus: | Cikk |
| Megjelent: |
2024
|
| Sorozat: | PERFUSION-LONDON
39 No. 4 |
| Tárgyszavak: | |
| doi: | 10.1177/02676591231160272 |
| mtmt: | 33734441 |
| Online Access: | http://publicatio.bibl.u-szeged.hu/26906 |
| LEADER | 02886nab a2200349 i 4500 | ||
|---|---|---|---|
| 001 | publ26906 | ||
| 005 | 20240704110709.0 | ||
| 008 | 230405s2024 hu o 000 eng d | ||
| 022 | |a 0267-6591 | ||
| 024 | 7 | |a 10.1177/02676591231160272 |2 doi | |
| 024 | 7 | |a 33734441 |2 mtmt | |
| 040 | |a SZTE Publicatio Repozitórium |b hun | ||
| 041 | |a eng | ||
| 100 | 1 | |a Zöllei Éva | |
| 245 | 1 | 0 | |a Venovenous extracorporeal membrane oxygenation for COVID-19 associated severe respiratory failure |h [elektronikus dokumentum] : |b Case series from a Hungarian tertiary centre / |c Zöllei Éva |
| 260 | |c 2024 | ||
| 300 | |a 790-796 | ||
| 490 | 0 | |a PERFUSION-LONDON |v 39 No. 4 | |
| 520 | 3 | |a Introduction Venovenous extracorporeal membrane oxygenation (V-V ECMO) is recommended for the support of patients with severe COVID-19 associated severe respiratory failure (SRF). We report the characteristics and outcome of COVID-19 patients supported with V-V ECMO in a Hungarian centre. Methods We retrospectively collected data on all patients admitted with proven SARS CoV-2 infection who received V-V ECMO support between March 2021 and May 2022. Results Eighteen patients were placed on ECMO during this period, (5 women, age (mean +/- SD) 44 +/- 10 years, APACHE II score (median (interquartile range)) 12 (10-14.5)). Before ECMO support, they had been hospitalised for 6 (4-11) days. Fifteen patients received noninvasive ventilation for 4 (2-8) days, two patients had high flow nasal oxygen therapy, for one day each. They had already been intubated for 2.5 (1-6) days. Prone position was applied in 15 cases. On the day before ECMO initiation the Lung Injury Score was 3.25 (3-3.26), the PaO2/FiO(2) ratio was 71 +/- 19 mmHg. The duration of V-V ECMO support was 26 +/- 20 days, and the longest run lasted 70 days. Patients were mechanically ventilated for 34 +/- 23 days. The intensive care unit (ICU) and the hospital length of stay were 40 +/- 28 days and 45 +/- 31 days, respectively. Eleven patients were successfully weaned from ECMO. The ICU survival rate was 56%, the in-hospital survival was 50%. All patients who were discharged from hospital reported a good health-related quality of life Rankin score (0-2) at the 5-16 months follow-up. Conclusions During the last three waves of the COVID-19 pandemic, we achieved a 56% ICU and a 50% hospital survival rate at our low volume centre. | |
| 650 | 4 | |a Klinikai orvostan | |
| 700 | 0 | 1 | |a Rudas László |e aut |
| 700 | 0 | 1 | |a Hankovszky Péter |e aut |
| 700 | 0 | 1 | |a Korsós Anita |e aut |
| 700 | 0 | 1 | |a Pálfi Alexandra |e aut |
| 700 | 0 | 1 | |a Varga Zoltán |e aut |
| 700 | 0 | 1 | |a Tomozi László |e aut |
| 700 | 0 | 1 | |a Hegedűs Zoltán |e aut |
| 700 | 0 | 1 | |a Bari Gábor |e aut |
| 700 | 0 | 2 | |a Lobozárné Szivós Brigitta |e aut |
| 700 | 0 | 2 | |a Kiszel Attila |e aut |
| 700 | 0 | 2 | |a Babik Barna |e aut |
| 856 | 4 | 0 | |u http://publicatio.bibl.u-szeged.hu/26906/1/Zollei.pdf |z Dokumentum-elérés |